Westermarck J. Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?. Molecular Oncology. 2023. Feb 28.
Pubmed →
Huuhtanen J. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. Journal of Clinical Investigation. 2023. Jan 31;e164809.
Pubmed →
Aakula A et al. RAS and PP2A activities converge on epigenetic gene regulation. Life Science Alliance. 2023 Mar 1;6(5):e202301928.
Pubmed →
Pavic K et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications. 2023 Feb 28;14(1):1143.
Pubmed →
Vaparanta K et al. An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation. Nature Communications. 2022. Nov 14;13(1):6953.
Pubmed →
Aakula A et al. PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers. Molecular Oncology. 2022. Dec 3. Online ahead of print.
Pubmed →
de Thonel A et al. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder. Nature Communications. 2022. Nov 16: 13;7002.
Link to Page→
Hu WT et al. CIP2A deficiency promotes depression-like behaviors in mice through inhibition of dendritic arborization. EMBO reports. 2022. Oct 28; e54911.
Link to Page→
Peuhu E et al. MYO10-filopodia support basement membranes at pre-invasive tumor boundaries. Developmental Cell. 2022. Oct 24: 57;20.
Link to Page→
Butt U et al. SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion, and metastasis. Journal of Cell Science. 2022. Sep 23;jcs.260627. Online ahead of print.
Pubmed→
Rytkönen KT et al. Cell type markers indicate distinct contributions of decidual stromal cells and natural killer cells in preeclampsia. Reproduction. 2022. Sep 1;REP-22-0079.
Pubmed→
Mohd Moin Khan et al. Long Intergenic Noncoding RNA MIAT as a Regulator of Human Th17 Cell Differentiation. Frontiers in Immunology. 2022. Jun 15;13:856762.
Pubmed→
